Combining a novel leucocyte–platelet-concentrated membrane and an injectable collagen scaffold in a single-step AMIC procedure to treat chondral lesions of the knee: a preliminary retrospective study

D’Antimo, C.; Biggi, Francesco; Borean, Alessio; Fabio, S. Di; Pirola, Ivan

doi:10.1007/s00590-016-1869-5

Cited by 19 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high density of RBCs, which are usually absent in most of the PRHs, is not relevant in the perspective of clinical application. LFPms are currently used in some preliminary clinical trials at the Orthopedic Department of Belluno Hospital (D'Antimo, Biggi, Borean, Di Fabio, & Pirola, ). Thus, they have already been tested for both autologous and allogeneic implants (preserving ABO/Rh compatibility) with no differences in the clinical outcome.…”

Section: Discussionmentioning

confidence: 99%

Biofabrication of a novel leukocyte-fibrin-platelet membrane as a cells and growth factors delivery platform for tissue engineering applications

Barbon

Stocco

Grandi

et al. 2018

J Tissue Eng Regen Med

Self Cite

View full text Add to dashboard Cite

Autologous platelet-rich hemocomponents have emerged as potential biologic tools for regenerative purpose, but their therapeutic efficacy still remains controversial. This work represents the characterization study of an innovative autologous leukocyte-fibrin-platelet membrane (LFPm), which we prepared according to a novel protocol involving multiple cycles of apheresis. The high content in fibrinogen gave to our hemocomponent the appearance of a manipulable and suturable membrane with high elasticity and deformation capacity. Moreover, being highly enriched with platelets, leukocytes, and monocytes/macrophages, the LFPm sustained the local release of bioactive molecules (platelet derived growth factor, vascular endothelial growth factor, interleukin-10, and tumour necrosis factor alpha). In parallel, the evaluation of stemness potential highlighted also that the LFPm contained cells expressing pluripotency and multipotency markers both at the messenger ribonucleic acid (NANOG, SOX2, THY1, NT5E, and ENG) and surface-protein level (CD44 /CD73 /CD34 /CD117 /CD31 ). Finally, biodegradation analysis interestingly showed a good stability of the membrane for at least 3 weeks in vitro and 1 week in vivo. In both cases, biodegradation was associated with progressive exposure of fibrin scaffold, loss/migration of cellular elements, and release of growth factors. Overall, collected evidence could shed some light on the regenerative effect that LFPms may exert after the autologous implant on a defect site.

show abstract

Section: Discussionmentioning

confidence: 99%

Biofabrication of a novel leukocyte-fibrin-platelet membrane as a cells and growth factors delivery platform for tissue engineering applications

Barbon

Stocco

Grandi

et al. 2018

J Tissue Eng Regen Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…After 2 and 5 year-follow ups, clinical scores [International Knee Documentation Committee (IKDC) functional scores, Visual Analogue Scale (VAS) pain], as well as MRI and Mocart scores revealed that the addition of platelet concentrates significantly improved microfractures outcome, with PRF ensuring better and earlier results than PRP [84]. Similarly, the work by D’Antimo and Collaborators [85] retrospectively investigated the regenerative effect of microfracture technique and the concomitant application of an autologous leucocyte- and platelet-rich fibrin membrane (CLP-MB). This hemocomponent is produced through blood collection by multiple apheresis cycles to obtain a leucocyte–platelet concentrate which is added to a plasma cryoprecipitate [9,10].…”

Section: Prf In Cartilage Tissue Engineeringmentioning

confidence: 95%

Platelet-Rich Fibrin Scaffolds for Cartilage and Tendon Regenerative Medicine: From Bench to Bedside

Barbon

Stocco

Macchi

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

Nowadays, research in Tissue Engineering and Regenerative Medicine is focusing on the identification of instructive scaffolds to address the requirements of both clinicians and patients to achieve prompt and adequate healing in case of injury. Among biomaterials, hemocomponents, and in particular Platelet-rich Fibrin matrices, have aroused widespread interest, acting as delivery platforms for growth factors, cytokines and immune/stem-like cells for immunomodulation; their autologous origin and ready availability are also noteworthy aspects, as safety- and cost-related factors and practical aspects make it possible to shorten surgical interventions. In fact, several authors have focused on the use of Platelet-rich Fibrin in cartilage and tendon tissue engineering, reporting an increasing number of in vitro, pre-clinical and clinical studies. This narrative review attempts to compare the relevant advances in the field, with particular reference being made to the regenerative role of platelet-derived growth factors, as well as the main pre-clinical and clinical research on Platelet-rich Fibrin in chondrogenesis and tenogenesis, thereby providing a basis for critical revision of the topic.

show abstract

“…Zwei Level-IV-Studien [31,37] mit insgesamt 38 Patienten und einem Follow-up von maximal 12 Monaten liegen für ChondroFiller gel (Amedrix GmbH, Esslingen, Deutschland) vor. In einer Studie, in der mehr als 50 % der Patienten nicht ihr Einverständnis für die Behandlung mit dem Biomaterial gaben und daher der Kontrollgruppe zugeführt wurden, war das Ergebnis im IKDC Score (International Knee Documentation Committee) in der Chondro-Filler gel -Gruppe nach 12 Monaten signifikant besser als präoperativ [37].…”

Section: Technische Aspekte Und Empfehlungen Für Débridement Und Markunclassified

Stellenwert der matrixaugmentierten Knochenmarkstimulation in der Behandlung von Knorpelschäden des Kniegelenks: Konsensusempfehlungen der AG Klinische Geweberegeneration der DGOU

Niemeyer

Brucker²,

Buhs³

et al. 2018

Z Orthop Unfall

View full text Add to dashboard Cite

Surgical principles for treatment of full-thickness cartilage defects of the knee include bone marrow stimulation techniques (i.e. arthroscopic microfracturing) and transplantation techniques (i.e. autologous chondrocyte implantation and osteochondral transplantation). On the basis of increasing scientific evidence, indications for these established therapeutical concepts have been specified and clear recommendations for practical use have been given. Within recent years, matrix-augmented bone marrow stimulation has been established as a new treatment concept for chondral lesions. To date, scientific evidence is limited and specific indications are still unclear. The present paper gives an overview of available products as well as preclinical and clinical scientific evidence. On the basis of the present evidence and an expert consensus from the "Working Group on Tissue Regeneration" of the German Orthopaedic and Trauma Society (DGOU), indications are specified and recommendations for the use of matrix-augmented bone marrow stimulation are given. In principle, it can be stated that the various products offered in this field differ considerably in terms of the number and quality of related studies (evidence level). Against the background of the current data situation, their application is currently seen in the border area between cell transplantation and bone marrow stimulation techniques, but also as an improvement on traditional bone marrow stimulation within the indication range of microfracturing. The recommendations of the Working Group have preliminary character and require re-evaluation after improvement of the study situation.

show abstract

Combining a novel leucocyte–platelet-concentrated membrane and an injectable collagen scaffold in a single-step AMIC procedure to treat chondral lesions of the knee: a preliminary retrospective study

Abstract: AMIC combined with the CLP-MB membrane, and Cartifill seems to be a promising approach to treat knee chondral defects.

Cited by 19 publications

References 29 publications

Biofabrication of a novel leukocyte-fibrin-platelet membrane as a cells and growth factors delivery platform for tissue engineering applications

Biofabrication of a novel leukocyte-fibrin-platelet membrane as a cells and growth factors delivery platform for tissue engineering applications

Platelet-Rich Fibrin Scaffolds for Cartilage and Tendon Regenerative Medicine: From Bench to Bedside

Stellenwert der matrixaugmentierten Knochenmarkstimulation in der Behandlung von Knorpelschäden des Kniegelenks: Konsensusempfehlungen der AG Klinische Geweberegeneration der DGOU

Contact Info

Product

Resources

About